Integrin agonists as adjuvants in chemotherapy for melanoma

Clinical Cancer Research

Volumn 14, Issue 19, 2008, Pages 6193-6197

  Schwartz, Martin A ^a,b   McRoberts, Kevin ^a   Coyner, Matthew ^a   Andarawewa, Kumari L ^a   Frierson Jr , Henry F ^b   Sanders, John M ^b   Swenson, Stephen ^c   Markland, Frank ^c   Conaway, Mark R ^a   Theodorescu, Dan ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN ANTIBODY; CONTORTROSTATIN; CYTARABINE; INTEGRIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TS2 16; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; APOPTOSIS; DRUG POTENTIATION; METABOLISM; METHODOLOGY; MOUSE MUTANT; ONCOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ADJUVANTS, PHARMACEUTIC; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYTARABINE; EXTRACELLULAR MATRIX; GENES, P53; HUMANS; INTEGRINS; MEDICAL ONCOLOGY; MELANOMA; MICE; MICE, SCID; SIGNAL TRANSDUCTION;

EID: 58149147360     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1285     Document Type: Article

References (21)

1. Zalaudek I, Ferrara G, Argenziano G, Ruocco V, Soyer HP. Diagnosis and treatment of cutaneous melanoma: a practical guide. Skinmed 2003;2:20-31.
2. Kasper B, D'Hondt V, Vereecken P, Awada A. Novel treatment strategies for malignant melanoma: a new beginning? Crit Rev Oncol Hematol 2007;62:16-22.
3. Schwartz MA, Assoian RK. Integrins andce ll proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. J Cell Sci 2001;114:2553-60.
4. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001;13:555-62.
5. Lewis JM, Truong TN, Schwartz MA. Integrins regulate the apoptotic response to DNA damage through modulation of p53. Proc Natl Acad Sci U S A 2002;99:3627-32.
6. Truong T, Sun G, Doorly M, Wang JYJ, Schwartz MA. Modulation of DNA damage-induced apoptosis by cell adhesion is independently mediated by p53 and c-Abl. Proc Natl Acad Sci U S A 2003;100:10281-6.
7. Lugassy C, Dickersin GR, Christensen L, et al. Ultrastructural and immunohistochemical studies of the periendothelial matrix in human melanoma: evidence for an amorphous matrix containing laminin. J Cutan Pathol 1999;26:78-83.
8. Van Duinen CM, Fleuren GJ, Bruijn JA. The extracellular matrix in pigmented skin lesions: an immunohistochemical study. Histopathology 1994;24:33-40.
9. Hofmann UB, Houben R, Brocker EB, Becker JC. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 2005;87:307-14.
10. Montgomery AM, De Clerck YA, Langley KE, Reisfeld RA, Mueller BM. Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res 1993;53:693-700.
11. Ritter MR, Zhou Q, Markland FS, Jr. Contortrostatin, a homodimeric disintegrin, actively disrupts focal adhesion andcyt oskeletal structure and inhibits cell motility through a novel mechanism. Cell Commun Adhes 2001;8:71-86.
12. Hogan KT, Coppola MA, Gatlin CL, et al. Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma. Cancer Res 2004;64:1157-63.
13. Orr AW, Sanders JM, Bevard M, Coleman E, Sarembock IJ, Schwartz MA. The subendothelial extracellular matrix modulates NF-κB activation by flow: apotential role inatherosclerosis. J Cell Biol 2005;169:191-202.
14. Luna LG. Histopathologic Methods and Color Atlas of Special Stains and Tissue Artifacts. American Histolabs Inc., Publications Division 1992.
15. Abend M. Reasons to reconsider the significance of apoptosis for cancer therapy. Int J Radiat Biol 2003;79:927-41.
16. Russell J, Ling CC. Studies with cytotoxic agents suggest that apoptosis is not a major determinant of clonogenic death in neuroblastoma cells. Eur J Cancer 2003;39:2234-8.
17. Chamber BA, Longo DL. Cancer chemotherapy and biotherapy. Lippincott, Williams and Wilkins; 2001.
18. Swenson S, Costa F, Ernst W, Fujii G, Markland FS. Contortrostatin, a snake venom disintegrin with antiangiogenic and anti-tumor activity. Pathophysiol Haemost Thromb 2005;34:169-76.
19. McGary EC, Lev DC, Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 2002;1:459-65.
20. Arroyo AG, Sanchez-Mateos P, Campanero MR, Martin-Padura I, Dejana E, Sanchez-Madrid F. Regulation of the VLA integrin-ligand interactions through the b1 subunit. J Cell Biol 1992;117:659-70.
21. Schwartz MA, Lechene C, Ingber DE. Insoluble fibronectin activates the Na/H antiporter by clustering andimmo bilizing integrin a5b1, independent of cell shape. Proc Natl Acad Sci U S A 1991;88:7849-53.